Sutacimig is a laboratory-engineered bispecific antibody being developed as the first-ever prophylactic treatment for individuals with Glanzmann thrombasthenia.

NBDF supports efforts to ensure patients with bleeding disorders can afford life-saving medications.

Hemgenix® is an adeno-associated virus (AAV) vector-based hemophilia gene therapy product received approval by the U.S. Food and Drug Administration in November 2022.

Congress extends short-term funding while major health programs hang in the balance. Get updates on ACA tax credits, Medicaid pricing, medical debt rules, and state actions impacting the bleeding disorders community.

VGA039 is a subcutaneous therapy designed to target the clot regulating protein known as Protein S to regulate excessive clotting and coagulation in people with all subtypes of VWD.

This booklet includes information about how inhibitors develop in people with hemophilia, key risk factors, and tips on getting screened.

This edition of the Resource Roundup includes resources that address everyday challenges universal to all caregivers as well as those unique to individuals with bleeding disorders.

The meeting convened researchers, industry leaders, nonprofit organizations, and lived experience experts to discuss ways to enhance the inclusion of women and girls with bleeding disorders in research.

This Arabic publication is an excellent resource for women and girls with hemophilia, caregivers, and health care providers who can utilize it to help inform shared decision making with their patients.

The pre-clinical stage biotech focused on RNA and nanomedicine.